First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.

被引：0
作者：
Plummer, R
Middleton, M
Wilson, R
Jones, C
Evans, J
Robson, L
Steinfeldt, H
Kaufman, R
Reich, S
Calvert, AH
机构：
[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[2] Churchill Hosp, Oncol Unit, Oxford OX3 7LJ, England
[3] Queens Univ Belfast, Dept Oncol, Belfast, Antrim, North Ireland
[4] Beatson Oncol Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland
[5] Canc Res UK, London, England
[6] Pfizer Global Res & Dev, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：208S / 208S
页数：1
相关论文
共 50 条
  • [31] A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.
    Rudin, C. M.
    Jimeno, A.
    Miller, W. H.
    Eigl, B. J.
    Gettinger, S. N.
    Chang, A. L. S.
    Faia, K.
    Sweeney, J.
    Loewen, G.
    Ross, R. W.
    Weiss, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors
    Moore, Kathleen N.
    Jones, Suzanne Fields
    Kurkjian, Carla
    Arkenau, Hendrik-Tobias
    Infante, Jeffrey R.
    Pant, Shubham
    Burris, Howard A.
    McMeekin, D. Scott
    Gibbons, Jay
    Harrow, Kimberly
    Liang, Chris
    Ramsey, Sara
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.
    Yap, Timothy A.
    Ahnert, Jordi Rodon
    Piha-Paul, Sarina Anne
    Fu, Siqing
    Janku, Filip
    Karp, Daniel D.
    Naing, Aung
    Dumbrava, Ecaterina Elena Ileana
    Pant, Shubham
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Hong, David S.
    Rose, Kelsey Meagan
    Xu, Quanyun
    Vellano, Christopher P.
    Mahendra, Mikhila
    Jones, Philip
    Di Francesco, Maria Emilia
    Marszalek, Joseph R.
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Phase I and pharimacokinetic trial of a novel inhibitor of NAD biosynthesis in patients with solid tumors.
    Holen, KD
    Bolling, C
    Saltz, LB
    Graefe, T
    Ty, V
    Sogo, N
    Starkmann, H
    Burk, KH
    Hollywood, E
    Hanauske, AR
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6158S - 6158S
  • [35] Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.
    Drew, Y.
    Ledermann, J. A.
    Jones, A.
    Hall, G.
    Jayson, G. C.
    Highley, M.
    Rea, D.
    Glasspool, R. M.
    Halford, S. E. R.
    Crosswell, G.
    Colebrook, S.
    Boddy, A. V.
    Curtin, N. J.
    Plummer, E. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors.
    Sarantopoulos, John
    Mahalingam, Devalingam
    Sharma, Neelesh
    Iyer, Renuka, V
    Wee, Wen
    Ahluwalia, Manmeet Singh
    Johnson, Saramarie
    Purmal, Andrei
    Shpigotskaya, Polina
    Hards, Ann
    Leonov, Andrey
    Gurova, Katerina
    Gudkov, Andrei
    Zakurdaeva, Kristina
    Miller, Langdon L.
    Dowlati, Afshin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors.
    Spencer, Kristen Renee
    Mehnert, Janice M.
    Tan, Antoinette R.
    Moss, Rebecca Anne
    Levinson, Kelly
    Stein, Mark N.
    Huzzy, Lien
    Kane, Michael P.
    Gibbon, Darlene
    Wright, John Joseph
    Aisner, Joseph
    DiPaola, Robert S.
    Chen, Suzie
    Wen, Yvonne
    Goydos, James
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Phase I trial of Amplimexon™ (imexon, inj.) in patients with advanced solid tumors.
    Dragovich, T
    Mendelson, D
    Gordon, M
    Wong, L
    Dorr, R
    Chow, S
    Grenier, K
    Hersh, E
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9122S - 9122S
  • [39] Phase I trial of weekly irinotecan plus docetaxel in patients with advanced solid tumors.
    Font, A
    Sánchez, JM
    Guillot, M
    Abad, A
    Taron, M
    Margelí, M
    Barnadas, A
    Rosell, R
    ANNALS OF ONCOLOGY, 2000, 11 : 141 - 141
  • [40] Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.
    Perets, Ruth
    Geva, Ravit
    McKean, Meredith
    Goutopoulos, Andreas
    Erez, Omri
    Phadnis, Monica
    Youssoufian, Hagop
    Schwartz, Brian E.
    Kansra, Vikram
    Fattaey, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345